ArticleBiochimica et biophysica acta. Molecular basis of disease2026
Regulation of PSAT1 and PHGDH by m6A in endocrine-resistant breast cancer cells.
Article in Biochimica et biophysica acta. Molecular basis of disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The N-6-methyladenosine (m6A) modification of mRNA regulates transcript abundance in endocrine therapy (ET)-resistant breast cancer (BCa) cells. We reported that m6A reader HNRNPA2B1 decreased miR-145p and miR-424-5p targeting PSAT1 and miR-34b-5p and miR-876-5p targeting PHGDH, thus stimulating the serine synthesis pathway (SSP) in ET-resistant BCa cells. Here we examined m6A regulation of PSAT1 and PHGDH. We report that siMETTL3 increased miR-145-5p, reducing PSAT1, and miR-34b-5p and miR-876-5p, reducing PHGDH, without affecting HNRNPA2B1 or NFkB and decreasing MYC, known to stimulate PSAT1 and PHGDH transcription. In contrast, the METTL3 inhibitor STM2457 increased METTL3, MYC, HNRNPA2B1, NFkB, PSAT1, PHGDH, and serine synthesis, and decreased the miRNAs. These data suggest that reducing METTL3 protein and inhibition of its catalytic activity have different effects on these targets. Selected results were verified in ET-resistant T47D and ZR-75-1 BCa cells. METTL3's stimulation of translation may play a role in these differences. Indeed, siMETTL3 had no effect on MYC, PHGDH, or PSAT1 pre-mRNA whereas STM2457 increased these pre-mRNAs. Overall, our data support a model for m6A regulation of PHGDH and PSAT1 indirectly through miRNAs that target PHGDH and PSAT1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.